The global gene editing market is distinguished by the presence of numerous global, regional, and local players catering to the gene editing techniques that are evolving at a rapid pace. Furthermore, the increasing funding for genetic research is further driving the growth of global gene editing market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in November 2021, GenScript launched the GenWand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.
The global gene editing market is extremely competitive, with players competing, partnering, and investing heavily in research and development to gain a significant market share. The market is moderately fragmented with rising competition, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers in the gene editing market are focusing on developing products with advanced technologies. It is also projected that a rise in the investments for R&D will also boost the market's growth in the upcoming future.
With respect to the current scope of the report, GE Healthcare (US) is the top player in the global gene editing market due to its strong product offering. Thermo Fisher Scientific Inc (US) is the second major player, followed by Bio-Rad Laboratories, Inc (US), Lonza (Switzerland), GenScript (US), Horizon Discovery Ltd (UK), OriGene Technologies, Inc (US), Integrated DNA Technologies, Inc (US), New England Biolabs, Inc (US), Sangamo Therapeutics (US).
Threat Of New Entrants
The threat of new entrants in the global gene editing market is moderate. Gene editing is a complex and rapidly evolving field, and significant investments in research and development are required to develop new technologies and applications. However, advances in gene editing techniques and the growing demand for gene editing products may attract new entrants to the market in the future. In addition, regulatory approval is required which adds a significant barrier to entry. Companies aim to increase their market share and capture the market share which is mostly untouched by major players. Hence, the threat of new entrants in the global gene editing market is expected to be relatively moderate.
Bargaining Power Of Suppliers
The bargaining power of suppliers in the global gene editing market is high as there is a limited number of suppliers in the market. Moreover, gene editing technologies require specialized equipment and materials, such as CRISPR-Cas9 systems and guide RNAs, and there are a limited number of suppliers that can provide these products. However, with the increasing number of companies and institutions involved in gene editing research and development, suppliers may decrease bargaining power in the future.
Threat Of Substitutes
The threat of substitutes in gene editing in the market is low. Gene editing is a unique and specialized field that has few direct substitutes. However, alternative therapies or treatments may be developed that could potentially compete with gene editing technologies in certain applications. There are several players offering similar products at competitive prices, which increases the threat of substitutes between players.
Bargaining Power Of Buyers
The bargaining power of buyers is moderate in the global gene editing market Gene editing technologies are in high demand, particularly for medical applications, and buyers have a wide range of options to choose from. However, the high cost of gene editing technologies and the regulatory requirements associated with their use may limit the bargaining power of buyers to some extent.
Intensity Of Rivalry
The degree of competition in the gene editing market is high owing to the market is dominated by a small number of established players, but there are a growing number of new entrants and start-ups that are developing novel gene editing technologies and applications. The intensity of competition is likely to increase as the market continues to grow and evolve. Companies must continue to invest in research and development to stay competitive and meet the changing needs of patients and healthcare providers. Such things might increase the level of product differentiation and will support the sales of the manufacturers.
